RESEARCH TRIANGLE PARK, NC--(Marketwire - November 21, 2008) - A recently published therapeutic
area forecasting report from pharmaceutical business intelligence leader
Cutting Edge Information finds that DPP-4 inhibitors will quickly become
the highest-grossing class within the diabetes market, even outpacing the
long-acting insulins.
The DPP-4 class entered the market in 2006 when Merck won approval to
market Januvia. The class has three distinct advantages setting it apart
from competitors: a lowered risk for hypoglycemia, a lowered risk for
weight gain, and an oral formulation. Though Januvia remains the only
FDA-approved DPP-4 inhibitor, two rivals are racing through development,
and both are expected to reach blockbuster status.
"With health scares linked to TZDs and GLP-1 analogs, the DPP-4 class has
become a lucrative research target within the diabetes field," says lead
author Jeremy Spivey. "Januvia will likely become the top-selling Type II
diabetes drug by 2012, and other companies are eager to produce DPP-4s of
their own."
"Diabetes Market Forecast to 2013"
(
http://cuttingedgeinfo.com/Diabetes/index.htm) examines trends affecting
the diabetes space today and their impact leading into the next decade. It
details the historical, current and forecasted performance of more than 50
drugs -- including marketed brands, pipeline products and those still in
development -- treating diabetes and its complications, as well as
analyzing the top seven drug makers in the diabetes market.
The report breaks diabetes data down by individual drug, class, and
company; and it identifies which drug classes have the most potential in a
highly competitive market. The structure leads to data comparisons and
analyses across multiple levels, and enables an honest appraisal of key
developments facing players in the diabetes space.
Brand and drug manufacturer profiles are also included. Brand profiles
detail a product's competitive and strategic positioning, market
opportunities, and patent and litigation status.
Profiles include the following information:
-- Drug's current and projected competitive strength
-- Current/projected sales position within drug class
-- Sales projection charts for the next four to seven years
-- Competitive assessment
-- Clinical trial information
Company profiles analyze seven companies with the top diabetes franchises
or exciting development pipelines. Profiles contain:
-- Company ranking in diabetes market
-- Overall industry ranking
-- Strengths analysis
-- Growth areas analysis
-- Competition analysis
-- Key products breakdown
Learn more about the report and download a brochure at
http://cuttingedgeinfo.com/Diabetes/index.htm
Contact Information: CONTACT INFORMATION:
Jeremy Spivey
919-433-0373